Surpassing insulin glargine in type 2 diabetes with tirzepatide

Abstract

In this centennial year of the isolation and purification of insulin by Banting and colleagues,1 insulin remains a mainstay of treatment for diabetes, being efficacious and cost-effective in controlling glycaemia in people with type 2 diabetes who are poorly controlled on maximal or near-maximal doses of oral hypoglycaemics. The basal analogue insulin glargine is often used as the first-choice injectable for this group, using the algorithm pioneered in the 2003 Treat-to-Target Trial (TTT),2 with progressive titration of insulin doses dependent on measurements of fasting glucose.